- Home
- GRCE vs RAPT Comparison
GRCE vs RAPT Comparison
Compare GRCE & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- RAPT
- Stock Information
- Founded
- GRCE 2002
- RAPT 2015
- Country
- GRCE United States
- RAPT United States
- Employees
- GRCE N/A
- RAPT N/A
- Industry
- GRCE
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GRCE
- RAPT Health Care
- Exchange
- GRCE NYSE
- RAPT Nasdaq
- Market Cap
- GRCE 30.9M
- RAPT 59.1M
- IPO Year
- GRCE N/A
- RAPT 2019
- Fundamental
- Price
- GRCE $3.24
- RAPT $1.16
- Analyst Decision
- GRCE
- RAPT Hold
- Analyst Count
- GRCE 0
- RAPT 10
- Target Price
- GRCE N/A
- RAPT $6.00
- AVG Volume (30 Days)
- GRCE 77.8K
- RAPT 1.2M
- Earning Date
- GRCE 02-14-2025
- RAPT 03-06-2025
- Dividend Yield
- GRCE N/A
- RAPT N/A
- EPS Growth
- GRCE N/A
- RAPT N/A
- EPS
- GRCE N/A
- RAPT N/A
- Revenue
- GRCE N/A
- RAPT N/A
- Revenue This Year
- GRCE N/A
- RAPT N/A
- Revenue Next Year
- GRCE N/A
- RAPT N/A
- P/E Ratio
- GRCE N/A
- RAPT N/A
- Revenue Growth
- GRCE N/A
- RAPT N/A
- 52 Week Low
- GRCE $2.13
- RAPT $0.79
- 52 Week High
- GRCE $4.97
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- RAPT 44.08
- Support Level
- GRCE N/A
- RAPT $1.07
- Resistance Level
- GRCE N/A
- RAPT $1.20
- Average True Range (ATR)
- GRCE 0.00
- RAPT 0.09
- MACD
- GRCE 0.00
- RAPT -0.01
- Stochastic Oscillator
- GRCE 0.00
- RAPT 42.86
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.